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Aim: Tyrosine kinase inhibitors are part of the armamentarium to treat metastatic renal 
cell carcinomas (mRCC). Costa Rica has approved sunitinib in the first line setting. The 
authors conducted a retrospective study to address the effectiveness and safety profile of 
sunitinib in our population in terms of overall survival (OS) and progression free survival 
(PFS). Methods: The authors analyzed all patients who were treated with sunitinib 
diagnosed with mRCC in the three National Hospitals (Hospital Mexico, Hospital San Juan 
de Dios, and Hospital Calderon Guardia) from February 2007 to June 2015. Demographics, 
safety profile, and efficacy (OS and PFS) were obtained from medical records. OS and PFS 
were calculated using the Kaplan Meier method and a Cox Proportional Model Analysis 
was used when OS and PFS were compared in subset of patients. Results: Seventy-seven 
patients were included; mean age was 58.9 years. Fifty-four patients were male (70.1%). 
The most common histologic type was clear cell carcinoma (87%), followed by papillary 
(9.1%) and chromophobe (2.0%) types. Median OS was 21.0 months [95% confidence 
interval (CI): 13.42-28.58]. Median PFS was 13.7 months (95% CI: 11.24-16.16). Patients 
aged 65 years or older experienced worse PFS and OS than younger patients (median PFS: 
8.2 vs. 17.6 months; P = 0.011) (median OS: 19.0 vs. 29.0 months; P = 0.022). Sunitinib was 
well tolerated and no serious side effects were reported. Conclusion: This is the first study 
in Central America showing that sunitinib, first line, in mRCC is as effective as reported in 
pivotal clinical trials and expanded use studies in terms of PFS and OS.
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INTRODUCTION
Renal cell carcinoma (RCC) accounts for about 3% 
of all adult cancers, is the 8th most common cancer 
in Central America and the 10th worldwide, and the 
clear-cell RCC (ccRCC) is its most frequent histologic 
subtype.[1-4]
Surgery remains the standard of care for localized 
disease, and can often be curative.[5,6] Unfortunately, 
metastatic RCC (mRCC) is found in approximately 
one third of patients.[7] Furthermore, RCC is extremely 
resistant to conventional chemotherapy.[8] That is why 
different treatment strategies had been developed, 
taking into account improvements in understanding 
RCC biology and tumor behavior. RCC is highly 
vascularized due to overexpression of vascular 
endothelial growth factor (VEGF) induced by alterations 
of the tumor suppressor gene, Von Hippel-Lindau 
(VHL), leading to the increase of hypoxia-inducible 
factors 1 alpha and 2 alpha, ending in angiogenesis.[9] 
This has allowed the development of VEGF inhibitors 
such as tyrosine-kinase inhibitors (TKIs), monoclonal 
antibodies against VEGF, and mammalian target of 
rapamycin (mTOR) inhibitors.[5]
In Costa Rica the National Health Care System 
(Caja Costarricense de Seguro Social, CCSS) has 
authorized the use of sunitinib to treat mRCC in first 
line setting.[10] Sunitinib is a multiple TKI, including the 
VEFG receptors (VEFGRs) and platelet-derived growth 
factor receptors, producing a strong antitumor action 
in mRCC[11] and is approved worldwide as upfront line 
treatment of mRCC, with the reporting of significant 
objective response rates and also superiority over 
interferon-alfa in progression-free survival (PFS), with 
a trend to increase overall survival (OS).[12,13]
In this retrospective study we evaluated the 
effectiveness of sunitinib in the Costa Rican population 
in terms of median overall survival (mOS), median 
progression free survival (mPFS) and its safety profile.
METHODS
Patients and study design
This is a retrospective study reviewing the medical 
records from a total of 77 patients treated with sunitinib 
as first-line therapy in mRCC. Data were collected 
between February 2007 and June 2015 in the three 
major hospitals (Hospital San Juan de Dios, Hospital 
Calderon Guardia and Hospital Mexico) in San Jose, 
Costa Rica. All patients were required to be at least 
18 years of age and to have histologically confirmed 
mRCC (regardless of histologic subtype). The Ethics 
Committees in each hospital approved this study. 
All patients received oral sunitinib maleate, 50 mg 
once daily for 4 weeks of a 6-week treatment cycle 
(4 weeks on, 2 weeks off). The dosage was reduced 
in some cases to 37.5 mg daily. Sunitinib was given 
until disease progression or unacceptable toxicity. 
Physical examination and clinical laboratory tests were 
performed approximately one or two days before each 
cycle. Adverse events were registered according to the 
National Cancer Institute (NCI) common terminology 
Criteria for Adverse Events (CTACAE), version 
3.0. Tumor evaluation was performed according 
to Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1.0, this assessment being done 
in accordance with local practices at each hospital. 
PFS was defined as from time of starting sunitinib to 
disease progression or death from any cause (death 
could occur within one month of the last treatment 
dose and was included in the PFS analysis). OS was 
defined as the time from start of sunitinib to death from 
any cause.
Statistical analysis
In this retrospective study we included all patients 
who received sunitinib during the observational period 
of time in Costa Rica. For that reason there were 
neither pre-specified sample sizes nor pre-established 
hypotheses to evaluate. Categorical variables are 
presented as percentages. Continuous variables 
are presented as the mean ± standard deviation. To 
assess the PFS and OS the Kaplan-Meier method 
was used. A Cox Proportional Model Analysis was 
employed to determine differences in the outcome 
variables according to age less or higher than 65 year. 
In addition univariate and multivariate analyses were 
used to explore the association between OS and PFS 
with prognostic factors. A P value less than 0.05 was 
considered statistically significant. Data were analyzed 
using SPSS for Mac version 20.0 (SPSS, Chicago, IL).
RESULTS
A total of 77 patients were included in the study. Patient 
characteristics are described in Table 1. All patients 
received sunitinib as first line treatment, while none 
was previously treated either with cytokines or TKIs. 
With a median follow-up of 18.9 months, mPFS was 
13.7 months [95% confidence interval (CI): 11.24-
16.16 months], and mOS was 21.0 months (95% CI: 
13.42-28.58 months) [Figure 1].
A statistically significant difference was found in 
terms of PFS and OS according to patient age, risk of 
progression as well as risk of death by disease. This 
was higher in patients 65 years or older in comparison 
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to those with less than 65 years. mPFS was 17.6 months 
(95% CI: 10.2-25.0 months) vs. 8.2 months (95% CI: 
0.1-16.4 months); hazard ratio (HR): 1.93 (95% CI: 1.2-
3.2); P = 0.011; mOS was 29.0 months (95% CI: 11.4-
46.5) vs. 19.0 months (95% CI: 11.0-26.9, HR = 1.82; 
95% CI = 1.1-3.1); P = 0.022 [Figure 2]. These findings 
were confirmed in univariate and multivariate analyses 
[Tables 3 and 4], showing that age was an independent 
prognostic factor either for PFS or OS.
There was no difference in PFS by gender or histological 
variant [Table 2]. However, a significant difference 
was found in mOS according to histological subtype 
in favor of ccRCC when compared with non-clear cell 
carcinoma: 26.8 months (95% CI: 20.1-30.5) vs. 14.2 
months (95% CI: 0-29.0); HR: 3.41 (95% CI: 1.6-7.3; 
P = 0.001) [Figure 3]. When univariate and multivariate 
analyses were performed, it was found that ccRCC was 
an independent prognostic factor in terms of OS but not 
PFS [Tables 3 and 4].
Sunitinib was, in general, well tolerated. There were 
17 patients (22%) who received a dose reduction to a 
37.5 mg daily schedule due to grade 1 or 2 toxicities; 
no grade 3 or 4 toxicities were registered. Diarrhea and 
hand-foot syndrome were the most commonly adverse 
reactions described [Table 5].
DISCUSSION
According to international RCC treatment guidelines, 
sunitinib is currently one of the preferred options 
to treat metastatic clear cell renal cell carcinoma 
(mccRCC).[14,15] Its efficacy and safety have been 
evaluated in a phase III pivotal study and the global 
expanded-access trial (GEAT).[16-18] There are few data 
in Latin America regarding the effectiveness of sunitinib. 
In the GEAT trial, it was reported that a subset analysis 
of 348 Latin American patients showed a mPFS and a 
mOS of 12.1 and 16.9 months, respectively.[19,20] The 
final analysis of this global trial including more than 
4,500 patients demonstrated a mPFS of 9.4 months 
and a mOS of 18.7 months.[18] In the present study we 
obtained a mPFS of 13.7 and a mOS of 21.0 months, 
very similar to the results reported globally. This strongly 
suggests that sunitinib has the same effectiveness in 
the Latin American population as previously assessed 
in the pivotal trial and the GEAT, supporting the use of 
Table 1: Patient characteristics
All patients (n = 77)
Median age (years, range)                  58.9 (47.4-70.4)
Patients older than 65 years (%)                         25 (32.4)
Gender (%)
Female
Male
                  23 (29.9)
                            54 (70.1)
ECOG/PS (%)
0
1
2
                           60 (77.9)
                            10 (12.9)
                         7 (9.2)
Histological variant (%)
Clear cell carcinoma
Papillary
Chromophobe
Collecting duct carcinoma
                       67 (87.0)
                               7 (9.1)
                          2 (2.6)
                              1 (1.3)
MSKCC risk classification (%)
Low
Intermediate
High
                        47 (61.0)
                                             25 (32.4)
                                5 (6.5)
Site of metastasis (%)
Lung
Bone
Liver
Central nervous system
Other
                          55 (52.8)
                           19 (18.3)
                           16 (15.3)
                          10 (9.6)
                            4 (3.8)
ECOG: Eastern Cooperative Oncology Group; PS: performance 
status; MSKCC: Memorial Sloan Kettering Cancer Center
Figure 1: (A) Probability of progression-free survival in all patients: 13.7 months (95% CI: 11.24-16.16 months); (B) probability of overall 
survival in all patients: 21.0 months (95% CI: 13.42-28.58 months). CI: confidence interval
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this drug as the standard of care in first line mRCC in 
Costa Rica.
Surprisingly, when analyzed by age, it was found that 
patients aged ≥ 65 years, experienced worse PFS and 
OS than younger patients (< 65), mPFS: 8.2 vs. 17.6 
months; (P = 0.011) and mOS: 19.0 vs. 29.0 months 
(P = 0.022). This was seen, as well, when univariate 
and multivariate analyses were performed. These 
findings have not been previously reported. Another 
study[21] published a retrospective pooled analysis from 
1059 patients in six prospective trials. The authors 
found that, across the entire pooled sunitinib-treated 
population in the first line setting, PFS and OS were 
not different in younger and elderly patient aged 70 
and ≥ 70 years, respectively: mPFS was 9.9 vs. 11.0 
months with a HR of 0.89 (95% CI: 0.73-1.09; P = 
0.2629), while mOS was 23.6 vs. 25.6 months, with an 
HR of 0.93 (95% CI: 0.74-1.18; P = 0.5442). Also, the 
GEAT study was not able to identify differences among 
patients by age, either regarding OS or PFS.[18] There 
is no clear explanation to these findings. However, 
Table 2: Progression-free survival and overall survival by gender and histological variant
mPFS mOS
Gender Female 10.8 months (95% CI: 3.1-18.5) 18.0 months (95% CI: 13.2-22.8)
Male 15.2 months (95% CI: 10.9-19.5) 23.0 months (95% CI: 16.2-29.7)
(HR:1.21; 95% CI: 0.71-2.0; P = 0.49) (HR: 1.23 95% CI: 0.71-2.11; P = 0.46)
Histology Clear cell carcinoma 15.2 months (95% CI: 10.8-19.7) 26.8 months (95% CI: 20.1-30.5)
Non-clear cell carcinoma 8.2 months (95% CI: 0-19.5) 14.2 months (95% CI: 0-29.0)
HR: 1.84 (95% CI: 0.9-3.76); P = 0.089 HR: 3.41 (95% CI: 1.6-7.3); P = 0.001)
CI: confidence interval; HR: hazard ratio; mPFS: median progression-free survival; mOS: median overall survival
Table 3: Univariate and multivariate analyses of potential prognostic variables for overall survival
Variable Univariate hazard ratio (95% CI) P value Multivariate hazard ratio (95% CI) P value
Male sex 0.77 (0.44-1.36) 0.372 0.88 (0.49-1.55) 0.659
Clear cell histology 0.29 (0.13-0.63) 0.002* 0.34 (0.16-0.76) 0.008
Age ≥ 65 years 2.15 (1.26-3.69) 0.005* 1.97 (1.14-3.04) 0.015*
CI: confidence interval
Table 4: Univariate and multivariate analyses of potential prognostic variables for progression-free survival
Variable Univariate hazard ratio (95% CI) P value Multivariate hazard ratio (95% CI) P value
Male sex 0.82 (0.48-1.41) 0.497 0.81 (0.46-1.42) 0.464
Clear cell histology 0.54 (0.26-1.12) 0.096 0.62 (0.27-1.31) 0.214
Age ≥ 65 years 2.21 (1.31-3.72) 0.003* 2.21 (1.30-3.76) 0.003*
CI: confidence interval
Table 5: Sunitinib-related toxicities*
Frequency (%)
None 24 (31.2)
Diarrhea 12 (15.6)
Fatigue 1 (1.3)
Hand-foot syndrome 11 (14.3)
Hypertension 2 (2.6)
Not reported 27 (35.1)
*Only grade 1 and 2 toxicities were reported
Figure 2: (A) Probability of progression-free survival according to age: less than 65 years: 17.6 months (95% CI: 10.2-25.0) and 8.2 months 
(95% CI: 0.1-16.4) in patients older than 65 years. HR = 1.93 (95% CI: 1.2-3.2); P = 0.011; (B) probability of overall survival according to 
age, 29.0 months (less than 65 years) (95% CI: 11.4-46.5) vs. 19.0 months (older than 65 years) (95% CI: 11.0-26.9) (HR = 1.82; 95% CI: 
1.1-3.1); P = 0.022. CI: confidence interval; HR: hazard ratio
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this could be due to intrinsic characteristics of the 
Costa Rican population. To address this observation, 
a different statistical analysis in this subset of patients 
was performed, including performance status, dosage 
received, and MSKCC risk. However, it was not 
possible to find a strong correlation with any of these 
factors. Thus, it could be possible that this is specific 
for Latin Americans. Further study might be warranted.
In accordance the pivotal sunitinib phase III trial, 
the GEAT study, and other mainly retrospective 
studies involving small number of patients[16,18,22-25] no 
differences by gender in terms of OS or PFS in the 
present study were found.
Sunitinib has shown only modest activity for the 
treatment of advanced and/or metastatic non-clear 
cell RCC, mPFS reported from 11 of 12 studies in a 
recently published systematic review ranged from 1.6 
to 8.9 months and mOS in 9 studies in the same review 
ranged from 12 to 22 months. Both mOS and mPFS 
are less than reported for mccRCC.[26] Interestingly, 
the present study obtained, in non-clear cell RCC, 
a mPFS of 8.2 months and a mOS of 14.2 months, 
keeping in line with the global literature. However, 
when an exploratory analysis comparing PFS and 
OS by histological variant was performed, mPFS for 
mccRCC was not statistical different from non-clear 
cell mRCC. Nevertheless, mOS was significantly 
superior in favor of mccRCC (26.8 months vs. 14.2 
months), a finding also confirmed in univariate and 
multivariate analyses. The explanation of this PFS, 
taking into account numerous confounders such small 
number of patients in the non-clear cell mRCC arm 
and possible patient selection bias, is that 7 patients 
had papillary histology and 1 had a chromophobe type, 
both histologies having demonstrated to be responders 
to TKIs.[27,28] With these findings, the use of sunitinib in 
either non-clear cell mRCC or mccRCC in the Costa 
Rican population can be supported.
Regarding the safety profile, sunitinib was well 
tolerated, with diarrhea and hand-foot syndrome being 
the most common adverse events, with no grade 3 or 4 
toxicities. In the GEAT study, diarrhea and fatigue were 
the most common side effects reported, and hand-foot 
syndrome was only in the 8th position.[18]
Although this study has some limitations due to its 
retrospective design and relatively small sample size, 
it provides real-world effectiveness of this treatment in 
this particular population.
In conclusion, sunitinib exerts important activity in 
mRCC in the Costa Rican population, demonstrated 
a mPFS and a mOS similar to pivotal and expanded 
access trials. Sunitinib seems to be more effective 
in younger patients than in patients aged 65 or more 
years. It is also well-tolerated regardless patients age.
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